RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

Andrea Bacigalupo, Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Guillermo Sanz, Noel Milpied, Mauricette Michallet, Didier Blaise, Jorge Sierra, Gérard Socié, Jan J. Cornelissen, Christoph Schmid, Sebastian Giebel, Norbert-Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin N. Savani, Mohamad Mohty, Eliane GluckmanArnon Nagler

Risultato della ricerca: Contributo in rivistaArticolo in rivista

23 Citazioni (Scopus)


Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. The aim of the current retrospective study was to compare transplantation outcomes of acute myeloid leukemia (AML) patients given UCBT after either RIC or MAC. Data from 894 adults with AML receiving a single or double UCBT as first allograft from 2004 to 2013 at EBMT centers were included in this study. 415 patients were given UCBT after RIC while 479 patients following a MAC. In comparison to MAC recipients, RIC recipients had a similar incidence of neutrophil engraftment and of acute and chronic graft-versus-host disease (GVHD). However, RIC recipients had a higher incidence of disease relapse and a lower NRM, translating to comparable leukemia-free (LFS), GVHD-free, relapse-free survival (GRFS) and overall survival (OS). These observations remained qualitatively similar after adjusting for differences between groups in multivariate analyses. In conclusion, these data suggest that LFS and OS are similar with RIC or with MAC in adults AML patients transplanted with UCBT. These observations could serve as basis for a future prospective randomized study.
Lingua originaleEnglish
pagine (da-a)43027-43038
Numero di pagine12
Stato di pubblicazionePubblicato - 2016


  • AML
  • Myeloablative
  • Oncology
  • Reduced-intensity
  • Transplantation
  • Unrelated cord blood


Entra nei temi di ricerca di 'RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT'. Insieme formano una fingerprint unica.

Cita questo